Table 3.
Clinical efficacy of MMX mesalamine in maintenance of remission (12 months) in patients with mild to moderate ulcerative colitis
| Study | N | Doses | Clinical and endoscopic remission (%) | Relapse rates at 12 months (%) |
|---|---|---|---|---|
| Kamm et al59 | 232 | MMX mesalamine 1.2 g twice daily | 68.5 | 6.8 |
| 219 | MMX mesalamine 2.4 g twice daily | 64.4 | 11.1 | |
| Prantera et al25 | 162 | MMX mesalamine 2.4 g once daily | 60.9a | 15.0 |
| 156 | Asacol 2.4 g once daily | 61.7a | 29.9 | |
| Kane et al26 | 167 | MMX mesalamine 2.4 g once daily | _ | 35.6a |
Note:
a
Primary endpoint.